Rado J P, Juhos E
J Clin Pharmacol. 1976 Jul;16(7):333-7. doi: 10.1002/j.1552-4604.1976.tb01529.x.
The influence of 1-deamino-8-D-arginine vasopressin (DDAVP), the new antidiutetic polypeptide without any side effects on plasma cortisol, was investigated in 30 healthy persons. A dose of 4 mug DDAVP administered intravenously induced a rise in plasma cortisol (hydrocortisone) levels greater than 3.5 mug/100 ml in 12 out of 20 persons studied. In this group (group I), the average increase at 15 minutes was 6.92+/-1.74 mug/100 ml (P less than 0.005), while in the remaining eight persons (group II) plasma cortisol levels decreased according to the usual normal daily rhythm. DDAVP, 80 mug, administered intranasally had no demonstrable influence on physiologic plasma cortisol regulation. On the basis of the present findings with relatively low doses, pituitary responsiveness (ACTH release) might be expected to occur in a higher percentage of persons after giving high intravenous doses of DDAVP. Further efforts are necessary to develop a safe vasopressin test for clinical examination of adenohypophyseal function.
在30名健康受试者中研究了新型抗利尿多肽1-去氨基-8-D-精氨酸加压素(DDAVP)对血浆皮质醇无任何副作用的影响。在所研究的20人中,静脉注射4微克DDAVP使12人的血浆皮质醇(氢化可的松)水平升高超过3.5微克/100毫升。在该组(I组)中,15分钟时的平均升高为6.92±1.74微克/100毫升(P<0.005),而其余8人(II组)的血浆皮质醇水平则按照通常的正常日节律下降。经鼻给予80微克DDAVP对生理性血浆皮质醇调节无明显影响。基于目前相对低剂量的研究结果,静脉给予高剂量DDAVP后,预计垂体反应性(促肾上腺皮质激素释放)在更高比例的人中会出现。为开发一种用于腺垂体功能临床检查的安全加压素试验,还需要进一步努力。